β-Hydroxybutyrate Exacerbates Hypoxic Injury by Inhibiting HIF-1α-Dependent Glycolysis in Cardiomyocytes—Adding Fuel to the Fire?

XiuRui Ma (✉ 1234maer@163.com )
Zhongshan Hospital Fudan University

Zhen Dong
Zhongshan Hospital Fudan University

jingyi Liu
Shanxi cardiovascular hospital

Leilei Ma
Zhongshan Hospital Fudan University

Xiaolei Sun
Zhongshan Hospital Fudan University

Rifeng Gao
Fifth People's Hospital of Shanghai Fudan University

Lihong Pan
Fudan University

Jinyan Zhang
Zhongshan Hospital Fudan University

Dilan A
Zhongshan Hospital Fudan University

Jian An
shanxi cardivascular hospital

Kai Hu
Zhongshan Hospital Fudan University

Aijun Sun
Zhongshan Hospital Fudan University

Junbo Ge
Zhongshan Hospital Fudan University

Research Article

Keywords: Beta-hydroxybutyrate, Hypoxia, Glycolysis, Hypoxia-Inducible Factor 27 1α
β-hydroxybutyrate exacerbates hypoxic injury by inhibiting HIF-1α-dependent glycolysis in cardiomyocytes—Adding fuel to the fire?

Xiurui Ma\textsuperscript{a,b}, Zhen Dong\textsuperscript{a,c,d,e,*}, Jingyi Liu\textsuperscript{b}, Leilei Ma\textsuperscript{a}, Xiaolei Sun\textsuperscript{a,c,d,*}, Rifeng Gao\textsuperscript{f}, Lihong Pan\textsuperscript{e}, Jinyan Zhang\textsuperscript{a}, Dilan A\textsuperscript{a}, Jian An\textsuperscript{b}, Kai Hu\textsuperscript{a}, Aijun Sun\textsuperscript{a,c,d,e,##}, Junbo Ge\textsuperscript{a,c,d,e}

**Affiliations:**

a. Department of Cardiology, Zhongshan Hospital, Human Phenome Institute, Fudan University, Shanghai 201203, China;
b. Department of Cardiology, Shan Xi Cardiovascular Hospital, Taiyuan, 030024, China;
c. Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China;
d. NHC Key Laboratory of Viral Heart Diseases and Key Laboratory of Viral Heart Diseases;
e. Academy of Medical Sciences Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China
f. Shanghai Fifth People’s Hospital, Fudan University, Shanghai, 200032, China

*Contributed equally to this work

## Corresponding author; Email: angelasunsh@163.com (A.S.).
Abstract

**Purpose:** Ketone body oxidation yields more ATP per mole of consumed oxygen than glucose. However, whether an increased ketone body supply in hypoxic cardiomyocytes and ischemic hearts is protective or not remains elusive. The goal of this study is to determine the effect of β-hydroxybutyrate (β-OHB), the main constituent of ketone bodies, on cardiomyocytes under hypoxic conditions and the effects of ketogenic diet (KD) on cardiac function in a myocardial infarction (MI) mouse model.

**Methods:** Adult mouse cardiomyocytes and MI mouse models fed a KD were used to research the effect of β-OHB on cardiac damage. qPCR, western blot analysis and immunofluorescence were used to detect the interaction between β-OHB and glycolysis. Live/dead cell staining and imaging, lactate dehydrogenase, Cell Counting Kit-8 assays, echocardiography and 2,3,5-triphenyltetrazolium chloride staining were performed to evaluate the cardiomyocyte death, cardiac function and infarct sizes.

**Results:** β-OHB level was significantly higher in acute MI patients and MI mice. Treatment with β-OHB exacerbated cardiomyocyte death and decreased glucose absorption and glycolysis under hypoxic conditions. These effects were partially ameliorated by inhibiting hypoxia-inducible factor 1α (HIF-1α) degradation via roxadustat administration in hypoxia-stimulated cardiomyocytes. Furthermore, β-OHB metabolisms were obscured in cardiomyocytes under hypoxic conditions. Additionally, MI mice fed a KD exhibited exacerbated cardiac dysfunction compared with control chow diet (CD)-fed MI mice.

**Conclusion:** Elevated β-OHB levels may be maladaptive to the heart under hypoxic/ischemic conditions. Administration of roxadustat can partially reverse these harmful effects by stabilizing HIF-1α and inducing a metabolic shift toward glycolysis for energy production.

**Keywords:** Beta-hydroxybutyrate; Hypoxia; Glycolysis; Hypoxia-Inducible Factor 1α
Funding: This work was supported by the National Science Fund for Distinguished Young Scholars (A.S.; 81725002) and the Shanghai Municipal Science and Technology Major Project (2017SHZDZX01).

Conflict of interest: The authors declare no conflict of interest.

Data availability: The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author contributions: Xiurui Ma, Zhen Dong and AiJun Sun conceived and designed the study. Jingyi Liu collected patient plasma and information. Xiurui Ma, Zhen Dong, Leilei Ma, Rifeng Gao, Lihong Pan, Jinyan Zhang, and Dilan A. performed the animal and cell culture experiments. Xiurui Ma, Aijun S, Xiaolei Sun, Jian An, Kai Hu and Junbo Ge interpreted the data. Xiurui Ma, Aijun Sun and Kai Hu wrote the manuscript. Aijun Sun and Junbo Ge supervised the study. Aijun S and Junbo G reviewed and edited the manuscript. All authors approved the final manuscript.

Compliance with ethical standards:

Ethics approval

All animal protocols performed in this study were approved by and complying with the guides of the Animal Care and Use Committee of the Zhongshan Hospital, Fudan University.

All patients information was obtained from hospital medical records, test databases, or direct interviews with patients. The study protocol was approved by the Ethics Committee of Shanxi Cardiovascular Hospital (clinical registry number: 2018002).

Consent to participate: Informed consent was obtained from all individual participants included in the study and the written informed consent was provided by each patient at the time of registration.

Consent for publication: Not applicable.
1 Introduction

The heart is a high energy-consuming organ; therefore, cardiac energy metabolism is essential for its normal biological and physiological functions\(^1\). Oxygen plays a critical role in cardiac energy metabolism because mitochondrial oxidative phosphorylation provides 95% of the ATP in the healthy, adult mammalian heart\(^{2-5}\).

Upon limited oxygen supply, the heart can switch from using oxygen-dependent substrates to more oxygen-efficient energy sources\(^\text{6}\). It has previously been shown that glucose yields 11% more ATP per consumed oxygen atom than fatty acids\(^\text{7}\). However, ketone body oxidation yields more ATP per mole of consumed oxygen than glucose\(^\text{8}\). When the heart experiences hypoxia, such as during a myocardial infarction (MI) or in response to other pathologies, including chronic intermittent hypoxia, sleep apnea, and anemia, the heart can decrease fatty acid oxidation and concomitantly increase its use of glucose and ketone bodies as energy substrates\(^\text{9}\).

There is a growing body of evidence showing that the increased utilization of glucose during periods of ischemia is cardioprotective\(^{\text{1, 6, 10}}\). However, it is not yet clear whether an increased use of ketone bodies under hypoxic conditions is adaptive or maladaptive in the heart.

It has been previously shown that the mammalian heart is capable of avid ketone body uptake and oxidation\(^\text{11}\). Furthermore, the role of ketone bodies in cardiometabolic health has been increasingly recognized. In an ischemia-reperfusion rat model, fasting-induced ketosis\(^\text{12}\) and intravenous injection of β-hydroxybutyrate (β-OHB), the main component of ketone bodies\(^\text{13}\), have been shown to attenuate ischemic injury. In a recent clinical trial, the beneficial effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, on the cardiovascular outcomes of patients with diabetes\(^\text{14}\) is thought to be associated with hyperketonemia\(^\text{15}\). It has also been suggested that the heart is better protected against MI in the fed state with a lower level of ketone bodies compared with the fasted state\(^\text{16}\). However, a recent study has shown that both glucose and β-OHB are positively associated with an increased risk of MI\(^\text{17}\). Dietary carbohydrate intake has been associated with a significant increase in cardiovascular mortality\(^\text{18}\) and an increased risk of subsequent coronary artery calcium progression\(^\text{19}\). Furthermore, long-term ketogenic diet-induced β-OHB accumulation has been shown to be detrimental to heart health by promoting cardiac fibrosis\(^\text{20}\).

Despite these controversial findings, there is currently limited research on the impact of high levels of ketone bodies on heart metabolic adaptations in response to hypoxia.

Here, we aim to investigate whether high ketone body levels can modulate cardiac substrate metabolism and/or induce functional alterations in hypoxic cardiomyocytes and mice after MI surgery.

2 Materials and Methods

2.1 Human peripheral blood collection

Human peripheral blood was collected from acute MI patients at Shanxi Cardiovascular Hospital, and peripheral blood samples from healthy volunteers served as controls. The patient characteristics are shown in Supplemental Table S1. The
clinical outcomes of the acute MI patients were assessed by N-terminal proB-type natriuretic peptide (NT-proBNP) levels and left ventricular ejection fractions (LVEFs), which were measured by echocardiography 7 days after acute MI.

The use of human peripheral blood for scientific purposes was approved by the Ethics Committee of Shanxi Cardiovascular Hospital. All methods were conducted in accordance with the approved guidelines and regulations. Written informed consent was obtained from all patients.

2.2 Adult cardiomyocyte isolation and culture

Cardiomyocytes were isolated from adult, male C57BL/6 mice (6–8 weeks old, weighing 20–22 g) that were obtained from the Shanghai Jiesijie Laboratory Animal Centre, according to institutional guidelines. The isolation of adult mouse cardiomyocytes was performed as described previously[21]. After euthanasia, the heart was exposed. Following injection of 7 mL EDTA buffer into the right ventricle, the aorta was clamped with forceps, and the heart was removed. Multiple rounds of injections to the apex of the heart were performed with the following: 10 mL EDTA buffer, 3 mL perfusion buffer, and 30 mL collagenase buffer containing collagen II, collagen IV, and proteins. The heart was then pulled apart using forceps and filtered through a 100-µm strainer to remove large tissue debris.

After three rounds of gravity sedimentation, the adult cardiomyocytes were resuspended in culture media. After enzymatic isolation, the cardiomyocytes were seeded onto laminin-coated coverslips (2×10⁴ cardiomyocytes/coverslip) in plating media (M199 culture media [Thermo-Fisher Scientific], penicillin-streptomycin [Gibco], and 5% fetal bovine serum [Gibco]) and cultured at 37°C for 2 h to facilitate attachment. Then, the cardiomyocytes were cultured in M199 culture media containing 0, 0.1, 0.5, 1, 5, 10, 20, 50, or 100 mM Na-β-OHB (Sigma-Aldrich) (Na-β-OHB media). The cardiomyocytes were cultured in these media for 12 h before hypoxia was induced. The cardiomyocytes used in the roxadustat experiments were cultured in Na-β-OHB media before hypoxia as well as treatment with 50 µM roxadustat (Dalian Meilun Biotechnology). To simulate hypoxia, cardiomyocytes were placed in a hypoxia incubator maintained at 37°C, 1% O₂, and 5% CO₂ for 12 h.

Human AC16 cardiomyocytes were maintained in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (Gibco).

2.3 Animals and surgical procedures

Male C57BL/6 mice (6–8 weeks old) were randomly assigned to be fed a normal chow diet (CD; 11 kcal% fat, 20 kcal% protein, 69 kcal% carbohydrates) or a low-carbohydrate, low-protein ketogenic diet (KD; 93.5 kcal% fat, 4.7 kcal% protein, 1.8 kcal% carbohydrates; Dyets #HF93.5) for 4 weeks. After the 4 weeks, permanent ligation of the left anterior descending artery (LAD) was performed to induce MI in the mice. Echocardiographic analysis was performed 1 day after MI surgery. Mice with LVEFs between 30–45% were used for further experiments and were continued
on their respective CD or KD. Echocardiographic analysis was repeated 4 weeks later. Sham mice underwent similar surgical procedures without LAD ligation.

All experimental procedures were conducted in accordance with the animal welfare guidelines. All animal protocols were approved by the Animal Care and Use Committee of the Zhongshan Hospital, Fudan University.

2.4 Statistics
The Student’s t-test was used to analyze parametric variables between two groups, and one-way analysis of variance (ANOVA) with a post-hoc test was used to compare parametric variables among three or more groups. Linear regression and Pearson correlation analyses were used to analyze the relationship between β-OHB levels and patient clinical outcomes. All values were presented as the mean ± standard deviation (SD), and n was used to refer to the sample size. A P-value <0.05 was considered statistically significant.

2.5 Experimental setup
Detailed descriptions of the experimental setup and chemicals, including quantitative PCR (qPCR) analysis, western blot analysis, immunofluorescence, ketone body assay, intracellular ATP, live/dead cell staining and imaging, lactate dehydrogenase (LDH) and Cell Counting Kit-8 (CCK-8) assays, echocardiography, 2,3,5-triphenyltetrazolium chloride (TTC) staining, plasmid construction and transfection and RNA interference, are given in the Supplementary Methods.

3 Results
3.1 β-OHB levels were increased in response to MI in humans and mice
Baseline characteristics, including age and the proportion of men to women, were not significantly different between the healthy volunteers and acute MI patients (Supplemental Table S1). The serum β-OHB levels were significantly higher in the acute MI patients (Figure 1a), indicating the in vivo formation of β-OHB during acute MI. The serum β-OHB levels were negatively correlated with LVEFs (Figure 1b) and were positively correlated with NT-proBNP levels (Figure 1c) in acute MI patients, indicating that β-OHB may be related to severe myocardial injury.

The serum β-OHB levels were also significantly higher in the MI mice compared with the sham mice (Figure 1d) and were negatively correlated with LVEFs (Figure 1e). Additionally, the myocardial β-OHB levels were significantly increased in the mice 3 days after MI surgery (Figure 1f).

3.2 β-OHB enhanced cardiomyocyte death under hypoxic conditions
The live/dead cell assay was used to determine whether β-OHB influenced the death of cardiomyocytes in response to 12 h of hypoxia. Cardiomyocytes were cultured with media containing different doses of β-OHB. Under normoxic conditions, treatment
with 1 mM, 10 mM, 20 mM, or 50 mM β-OHB did not affect the percent of live cells. However, after 12 h of hypoxia, β-OHB decreased the percent of live cells in a dose-dependent manner (Figure 2a, b). Cell survival was determined using the CCK-8 assay, and results similar to those of the live/dead cell assay were observed (Figure 2c). As expected, β-OHB treatment increased necrotic cell death, as demonstrated by increased LDH release into the culture media (Figure 2d).

3.3 β-OHB altered glycolysis in cardiomyocytes under hypoxic conditions

Our results confirmed that the expression of a glycolytic glucose transporter, GLUT1, was upregulated in cardiomyocytes after 12 h of hypoxia. Accordingly, both the mRNA and protein expression levels of an important glycolytic regulator, PFKFB3, as well as other glycolytic rate-limiting enzymes, including HK2, PKM1, and LDHA, were all upregulated after 12 h of hypoxia compared with the control normoxia group (Figure 3a–f, h–k).

To further demonstrate the influence of β-OHB on glycolysis in cardiomyocytes, the cells were treated with different doses of β-OHB before undergoing 12 h of hypoxia. Western blot analysis showed that the protein expression levels of GLUT1, HK2, PFKFB3, PKM1, and LDHA decreased in response to β-OHB treatment in a dose-dependent manner compared with the vehicle control group (Figure 3a–f), suggesting decreased glucose absorption and glycolysis in the β-OHB-treated cardiomyocytes under hypoxic conditions. Furthermore, immunofluorescence revealed low levels of GLUT1 expression in the nuclei and cytoplasm of the β-OHB-treated cardiomyocytes (Figure 3g). Similar to the Western blot results, the mRNA expression levels of the glycolytic enzymes were also decreased in a dose-dependent manner in response to β-OHB treatment under hypoxic conditions (Figure 3h–k).

Because GLUT1 expression was decreased in response to β-OHB treatment, we measured the glucose concentrations in the culture media as an indicator of cellular glucose uptake. The media glucose concentrations proportionally increased with the dose of β-OHB, indicating that β-OHB decreased cellular glucose transportation (Figure 3l). Altogether, these results demonstrated that β-OHB inhibited cellular glucose uptake and glycolysis under hypoxic conditions.

3.4 β-OHB downregulated HIF-1α in cardiomyocytes in a dose-dependent manner under hypoxic conditions

Next, the expression of glycolysis regulator HIF-1α was analyzed. Consistent with our observation of decreased glycolysis in the β-OHB-treated cardiomyocytes, HIF-1α expression was also significantly downregulated in these cells. Cardiomyocytes exhibited significantly higher levels of HIF-1α in response to hypoxia compared with normoxia. However, high-dose β-OHB treatment resulted in decreased HIF-1α expression under hypoxic conditions (Figure 4a–d). High levels of HIF-1α were detected in the nuclei of cardiomyocytes after 12 h of hypoxia, thus indicating HIF-1α pathway activation. However, these levels were significantly reduced with β-OHB
8

treatment (Figure 5a, b). HIF-1α mRNA levels were also elevated in the
2 cardiomyocytes in response to hypoxia, but these levels remained unchanged after
3 β-OHB treatment (Figure 5e), indicating that β-OHB decreased HIF-1α at the
4 posttranslational level.
5 Additionally, AC16 human cardiomyocyte cells were transfected with HIF-1α siRNA,
6 which resulted in reduced HIF-1α and GLUT1 expression. This result was similar to
7 what was observed in response to β-OHB treatment (Figure 4f, h). Furthermore,
8 HIF-1α overexpression in AC16 cells suppressed the effects of β-OHB treatment
9 (Figure 4g, i). These results indicated that β-OHB reduced cellular glucose uptake via
10 the HIF-1α signaling pathway.
11
3.5 Roxadustat partially reversed the effects of β-OHB in cardiomyocytes under
12 hypoxic conditions
13 A HIF prolyl hydroxylase inhibitor, roxadustat (Roxa), was used in further
14 experiments to determine if it could reverse the effects of β-OHB by increasing
15 HIF-1α levels. Western blot and immunofluorescence analyses were used to examine
16 the expression of both HIF-1α and GLUT1 and confirmed that roxadustat
17 administration partially reversed the effects of β-OHB. Immunofluorescence results
18 showed that roxadustat administration partially reversed the effects of β-OHB (Figure
19 5a, b). Additionally, Western blot confirmed elevated HIF-1α levels after roxadustat
20 administration in cardiomyocytes under normoxic conditions. Roxadustat also
21 resulted in elevated HIF-1α expression in cardiomyocytes under hypoxic conditions
22 after β-OHB treatment (Figure 5c, d).
23 Next, GLUT1 expression was evaluated after roxadustat administration as a
24 downstream indicator of HIF-1α activity. Western blot and immunofluorescence
25 analyses both revealed that roxadustat administration increased GLUT1 expression in
26 cardiomyocytes treated with 10 mM β-OHB under hypoxic conditions (Figure 5c, e, f,
27 h).
28 Furthermore, the live/dead cell assay showed that roxadustat administration
29 substantially diminished cardiomyocyte death in response to β-OHB treatment under
30 hypoxic conditions (Figure 5g, i).
31 Then VHL expression was evaluated after roxadustat administration to explore the
32 mechanism of HIF-1α degradation. Western blot analyses revealed that β-OHB
33 upregulated VHL in cardiomyocytes in a dose-dependent manner under hypoxic
34 conditions and roxadustat administration decreased VHL expression in
35 cardiomyocytes treated with 10 mM β-OHB under hypoxic conditions (Figure 5j, k).
36
3.6 β-OHB metabolisms were obscured under hypoxic conditions in cardiac
37 myocytes.
38 Upon entering the cell, ketone bodies rapidly form acetyl-CoA via a series of
39 reactions catalyzed by BDH1, OXCT1, and mitochondrial acetyl-CoA
40 acetyltransferase 1 (ACAT1), as shown in Figure 6a. The levels of β-OHB were first
detected to observe its metabolism under hypoxic conditions in cardiomyocytes. Under normoxic conditions, β-OHB treatment did not result in elevated β-OHB levels in cardiomyocytes. However, under hypoxic conditions, β-OHB treatment resulted in increased intracellular β-OHB levels in cardiomyocytes in a dose-dependent manner (Figure 6b). Furthermore, the decreased expression of transporter SLC16A1 and the enzyme BDH1 were observed after β-OHB treatment, suggesting a low ketone body metabolic capacity in the cardiomyocytes under hypoxic conditions (Figure 6c, d).

Although β-OHB is an energy substrate, there was no change in ATP production in response to β-OHB treatment (Figure 6e). In contrast to the increased ketone utilization previously reported in end-stage heart failure[22] and HFrEF (heart failure with preserved ejection fraction)[23], the β-OHB treatment did not contribute to cardiomyocyte ATP production under hypoxic conditions, suggesting that the cardiomyocytes did not use ketone bodies as an alternative energy source.

3.7 KD exacerbated cardiac dysfunction in mice after MI surgery

Mice were fed either a KD or control CD for 4 weeks prior to MI surgery (Supplemental Table S2). The KD-fed mice exhibited higher plasma β-OHB levels compared with the CD-fed mice (Figure 7a). Infarct sizes and cardiac function were evaluated 4 weeks after MI surgery. Compared with the CD-fed mice, infarct size was larger in the KD-fed mice (Figure 7b, c) and cardiac function was worse in the KD-fed mice (Figure 7d–f) at 4 weeks post MI surgery. These data suggested that KD enhanced MI-induced cardiac injury.

4 Discussion

In this study, we demonstrated that plasma β-OHB levels were elevated in acute MI patients compared with healthy control volunteers, and increased β-OHB levels were also correlated with disease progression. Furthermore, β-OHB treatment resulted in the increased death of adult mouse cardiomyocytes in response to hypoxia as well as larger infarct sizes and deteriorated cardiac function in mice after MI surgery. Metabolic characteristics can influence the function and fate of cardiomyocytes[24]. Under hypoxic conditions, cardiomyocytes have been shown to utilize anaerobic glycolysis instead of oxidative phosphorylation to meet their energy demands and to reduce damage[25]. Here, we showed that β-OHB treatment decreased glycolysis in cardiomyocytes under hypoxic conditions and that downregulated HIF-1α was a key cause of this effect. The HIF prolyl hydroxylase inhibitor, roxadustat, had a therapeutic effect in the β-OHB-treated cardiomyocytes under hypoxic conditions, which was mostly due to increased levels of HIF-1α and GLUT1. In contrast to the alternative ketone utilization observed in advanced-stage heart failure, increased β-OHB utilization was not observed in cardiomyocytes under hypoxic conditions. However, intracellular β-OHB accumulation occurred in these cardiomyocytes and resulted in HIF-1α destabilization (Figure 8).

Elevated β-OHB concentrations have been found to be significantly higher in the hearts of patients with arrhythmogenic cardiomyopathy than in non-diseased donor
hearts[26]. Furthermore, increased concentrations of serum ketone bodies, but
decreased concentrations of myocardial ketone bodies, have been detected in patients
with dilated myocardial disease[27]. In our study, we demonstrated that β-OHB levels
were increased in both the serum of acute MI patients as well as the cardiomyocytes
of mice after MI surgery; however, β-OHB metabolism was not increased in
cardiomyocytes under hypoxic conditions. This observation is obscure because it is
contradictory to the alterative ketone utilization observed in advanced-stage heart
failure. Previous research has shown that hypertrophied and failing hearts undergo
regulatory gene reprogramming to increase the uptake and oxidation of ketone
bodies[23, 28]. Specifically, the expression of BDH1 and the transporter SLC16A1
have been shown to be increased during heart failure[22]. However, we found that
cardiomyocytes exhibited decreased expression levels of BDH1 and SLC16A1 in
response to hypoxia with β-OHB treated environment.

It is known that enhanced myocardial cell glucose metabolism increases cardiac
tolerance to ischemic injury[29]. In this study, glycolysis increased in cardiomyocytes
in response to hypoxia; however, elevated levels of β-OHB decreased glycolysis.
Therefore, alterations in this metabolic mode due to elevated β-OHB levels may
contribute to the decreased adaptability of cardiomyocytes in response to hypoxia.
These observations support the hypothesis that ketone body metabolism can regulate
the energy source selection of cardiomyocytes under hypoxic conditions.

It is known that HIF-1α regulates the expression of key glycolytic genes, including
glucose transporters GLUT1 and GLUT4, LDH, phosphoglycerate kinase (PGK1),
glucose-6-phosphate isomerase (GPI), and PFK1[30]. Our data showed that β-OHB
decreased the expression of HIF-1α in cardiomyocytes under hypoxic conditions and
also downregulated the expression of the glycolysis-associated proteins, GLUT1,
PKM1, and LDHA. Furthermore, the expression of HIF-1α decreased after β-OHB
treatment, and this effect was partially reversed by roxadustat. Therefore, our data
collectively indicate that normal glycolysis in cardiomyocytes may be partially
regulated by β-OHB via its regulation of HIF-1α. Because HIF-1α is essential for
cellular and systemic responses to low oxygen availability, reduced HIF-1α levels
may therefore be responsible for the increased death of cardiomyocytes under hypoxic
conditions[31].

HIF-1 plays a dominant role during cellular adaptation in response to changes in
oxygen availability. HIF-1 comprises two subunits: the hypoxia-regulated α subunit,
HIF-1α, and the oxygen-insensitive β subunit, HIF-1β[32]. Under normoxic
conditions, HIF-1α is rapidly degraded via the von Hippel-Lindau tumor suppressor
(pVHL)-mediated ubiquitin-proteasome pathway[33-35]. The association of pVHL
and HIF-1α under normoxic conditions is triggered by the posttranslational
hydroxylation of prolines (Pro402 and Pro564) by specific HIF prolyl
hydroxylases[36]. In our study, β-OHB decreased the protein level of HIF-1α in the
cardiomyocytes after hypoxia, but the mRNA levels remained unchanged and
stabilization of HIF by roxadustat through inhibiting the prolyl hydroxylases can
partially reversed the effects of β-OHB. So the mechanism of declining HIF-1α may
be partly prolyl hydroxylases-VHL dependent. Furthermore our data collectively indicate that β-OHB metabolism was obscured and β-OHB accumulation in cardiomyocytes under hypoxic, so the stability of HIF-1α may be modulated by β-OHB itself not the productions of its metabolism.

In the current study, we revealed that the β-OHB/HIF-1α/glycolysis pathway was associated with cardiac injury under hypoxic conditions. However, several questions remain. First, roxadustat only partially reversed the decreased expression of GLUT1 in response to β-OHB treatment under hypoxic conditions, suggesting that it did not completely reverse the effects of the β-OHB-mediated HIF-1α protein degradation. Further studies are required to reveal if β-OHB independently regulates HIF-1α stability. Second, in contrast to what we observed under hypoxic conditions, we observed increased levels of the glycolytic metabolites, PFKFB3, HK2, and PKM1, in β-OHB-treated cardiomyocytes under normoxic conditions. Nonetheless, our goal of this study was to confirm the contribution of the β-OHB/HIF-1α/glycolysis pathway to hypoxic injury. Therefore, we did not investigate the mechanism of these β-OHB-mediated effects under normoxic conditions. Third, besides glycolysis, HIF-1α has many downstream effects. Further studies are required to reveal the regulatory effects of β-OHB on myocardial injury in response to hypoxia. Last, we validated that β-OHB metabolism inhibited HIF-1α-dependent glycolysis in cardiomyocytes under hypoxic conditions. However, the mechanism of this β-OHB-mediated regulation of HIF-1α remains unclear and warrants further investigation.

In conclusion, our results demonstrated that increased β-OHB levels may be maladaptive to cardiomyocytes under hypoxic conditions. Therefore, patients with high levels of β-OHB may experience extensive injury due to ischemic heart disease, and a KD should not be recommended for individuals who have an increased risk of MI.
References

1. Li T, Zhang Z, Kolwicz SC, et al. Defective Branched-Chain Amino Acid Catabolism Disrupts Glucose Metabolism and Sensitizes the Heart to Ischemia-Reperfusion Injury. *Cell Metabolism.* 2017;25(2):374-85. [http://doi.org/10.1016/j.cmet.2016.11.005](http://doi.org/10.1016/j.cmet.2016.11.005)

2. Bing RJ, Siegel A, Ungar I, and Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. *Am J Med.* 1954;16(4):504-15. [http://doi.org/10.1016/0002-9343(54)90365-4](http://doi.org/10.1016/0002-9343(54)90365-4)

3. Wisneski JA, Gertz EW, Neese RA, and Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. *J Clin Invest.* 1987;79(2):359-66. [http://doi.org/10.1172/jci112820](http://doi.org/10.1172/jci112820)

4. Lopaschuk GD, Belke DD, Gamble J, Itoi T, and Schönekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. *Biochim Biophys Acta.* 1994;1213(3):263-76. [http://doi.org/10.1016/0005-2760(94)00082-4](http://doi.org/10.1016/0005-2760(94)00082-4)

5. van der Vusse GJ, van Bilsen M, and Glatz JF. Cardiac fatty acid uptake and transport in health and disease. *Cardiovasc Res.* 2000;45(2):279-93. [http://doi.org/10.1016/s0008-6363(99)00263-1](http://doi.org/10.1016/s0008-6363(99)00263-1)

6. Li X, Liu Y, Ma H, et al. Enhancement of Glucose Metabolism via PGC-1α Participates in the Cardioprotection of Chronic Intermittent Hypobaric Hypoxia. *Frontiers in Physiology.* 2016;7:219. [http://doi.org/10.3389/fphys.2016.00219](http://doi.org/10.3389/fphys.2016.00219)

7. Doenst. T, Nguyen. TD, and Abel. ED. Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production. *Circ Res.* 2013;113(6):709-24. [http://doi.org/10.1016/j.circres.2013.07.027](http://doi.org/10.1016/j.circres.2013.07.027)

8. Kashiwaya Y, Sato K, Tsuchiya N, et al. Control of glucose utilization in working perfused rat heart. *J Biol Chem.* 1994;269(41):25502-14.

9. Ritterhoff J, and Tian R. Metabolism in cardiomyopathy: every substrate matters. *Cardiovascular Research.* 2017;113(4):411-21. [http://doi.org/10.1093/cvr/cvx017](http://doi.org/10.1093/cvr/cvx017)

10. Ussher JR, Wang W, Gandhi M, et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. *Cardiovascular research.* 2012;94(2):359-69. [http://doi.org/10.1093/cvr/cvs129](http://doi.org/10.1093/cvr/cvs129)

11. Nakamura M, and Sadoshima J. Ketone body can be a fuel substrate for failing heart. *Cardiovasc Res.* 2019;115(11):1567-9. [http://doi.org/10.1093/cvr/cvx104](http://doi.org/10.1093/cvr/cvx104)

12. ŠNOREK1. M, HODYC. D, ŠEDIVÝ. V, et al. Short-Term Fasting Reduces the Extent of Myocardial Infarction and Incidence of Reperfusion Arrhythmias in Rats. *Physiol Res.* 2012;61:567-74. [http://doi.org/10.33549/physiolres.932338](http://doi.org/10.33549/physiolres.932338)

13. Zou Z, Sasaguri S, Rajesh KG, and Suzuki R. dl-3-Hydroxybutyrate administration prevents myocardial damage after coronary occlusion in rat hearts. *Am J Physiol Heart Circ Physiol.* 2002;283(5):H1968-74. [http://doi.org/10.1152/ajpheart.00250.2002](http://doi.org/10.1152/ajpheart.00250.2002)

14. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med.* 2015;373(22):2117-28. [http://doi.org/10.1056/NEJMoa1504720](http://doi.org/10.1056/NEJMoa1504720)

15. Ferrannini E, Mark M, and Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. *Diabetes Care.* 2016;39(7):1108-14. [http://doi.org/10.2337/dc16-0330](http://doi.org/10.2337/dc16-0330)

16. Liepinsh E, Makrecka M, Kuka J, et al. The heart is better protected against myocardial...
infarction in the fed state compared to the fasted state. *Metabolism.* 2014;63(1):127-36. [http://doi.org/10.1016/j.metabol.2013.09.014](http://doi.org/10.1016/j.metabol.2013.09.014)

17. Holmes MV, Millwood IY, Kartsonaki C, et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. *J Am Coll Cardiol.* 2018;71(6):620-32. [http://doi.org/10.1016/j.jacc.2017.12.006](http://doi.org/10.1016/j.jacc.2017.12.006)

18. Seidelmann SB, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. *The Lancet Public Health.* 2018;3(9):e419-e28. [http://doi.org/10.1016/s2468-2667(18)30135-x](http://doi.org/10.1016/s2468-2667(18)30135-x)

19. Gao J-W, Hao Q-Y, Zhang H-F, et al. Low-Carbohydrate Diet Score and Coronary Artery Calcium Progression. *Arteriosclerosis, thrombosis, and vascular biology.* 2020. [http://doi.org/10.1161/atvbaha.120.314838](http://doi.org/10.1161/atvbaha.120.314838)

20. Xu S, Tao H, Cao W, et al. Ketogenic diets inhibit mitochondrial biogenesis and induce cardiac fibrosis. *Signal Transduction and Targeted Therapy.* 2021;6(1). [http://doi.org/10.1038/s41392-020-00411-4](http://doi.org/10.1038/s41392-020-00411-4)

21. Ackers-Johnson M, Li PY, Holmes AP, O’Brien S-M, Pavlovic D, and Foo RS. A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Nonmyocytes From the Adult Mouse Heart. *Circulation research.* 2016;119(8):909-20. [http://doi.org/10.1161/CIRCRESAHA.116.309202](http://doi.org/10.1161/CIRCRESAHA.116.309202)

22. Aubert G, Martin OJ, Horton JL, et al. The Failing Heart Relies on Ketone Bodies as a Fuel. *Circulation.* 2016;133(8):698-705. [http://doi.org/10.1161/CIRCULATIONAHA.115.017355](http://doi.org/10.1161/CIRCULATIONAHA.115.017355)

23. Yan Deng, Maodi Xiea, Qian Lia, et al. Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF. *Circulation Research* 2020. [http://doi.org/10.1161/CIRCRESAHA.120.317933](http://doi.org/10.1161/CIRCRESAHA.120.317933)

24. Kolwicz SC, Purohit S, and Tian R. Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes. *Circulation Research.* 2013;113(5):603-16. [http://doi.org/10.1161/circresaha.113.302095](http://doi.org/10.1161/circresaha.113.302095)

25. Shao D, and Tian R. Glucose Transporters in Cardiac Metabolism and Hypertrophy. *Comprehensive Physiology.* 2015;6(1):331-51. [http://doi.org/10.1002/cphy.c150016](http://doi.org/10.1002/cphy.c150016)

26. Song JP, Chen L, Chen X, et al. Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy. *Sci Transl Med.* 2020;12(530). [http://doi.org/10.1126/scitranslmed.aay8329](http://doi.org/10.1126/scitranslmed.aay8329)

27. Bedi KC, Jr., Snyder NW, Brandimarto J, et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. *Circulation.* 2016;133(8):706-16. [http://doi.org/10.1161/CIRCULATIONAHA.115.017545](http://doi.org/10.1161/CIRCULATIONAHA.115.017545)

28. Selvaraj S, Kelly DP, and Margulies KB. Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. *Circulation.* 2020;141(22):1800-12. [http://doi.org/10.1161/circulationaha.119.045033](http://doi.org/10.1161/circulationaha.119.045033)

29. Rowe GC, Jiang A, and Arany Z. PGC-1 coactivators in cardiac development and disease. *Circ Res.* 2010;107(7):825-38. [http://doi.org/10.1161/CIRCRESAHA.110.223818](http://doi.org/10.1161/CIRCRESAHA.110.223818)

30. Zhong L, D’Urso A, Toiber D, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. *Cell.* 2010;140(2):280-93. [http://doi.org/10.1016/j.cell.2009.12.041](http://doi.org/10.1016/j.cell.2009.12.041)

31. Semenza GL. Hypoxia-Inducible Factor 1 and Cardiovascular Disease. *Annual review of physiology.* 2014;76:39-56. [http://doi.org/10.1146/annurev-physiol-021113-170322](http://doi.org/10.1146/annurev-physiol-021113-170322)
32. Wang GL, Jiang BH, Rue EA, and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510-4. http://doi.org/10.1073/pnas.92.12.5510

33. Salceda S, and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997;272(36):22642-7. http://doi.org/10.1074/jbc.272.36.22642

34. Huang LE, Gu J, Schau M, and Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998;95(14):7987-92. http://doi.org/10.1073/pnas.95.14.7987

35. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-5. http://doi.org/10.1038/20459

36. Bruick RK, and McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337-40. http://doi.org/10.1126/science.1066373

**Figure legends**

**Fig. 1** β-OHB levels were increased in response to MI in humans and mice. a Plasma β-OHB levels in healthy volunteers (n = 32) or AMI patients (n = 45), b Linear regression and Pearson correlation analysis of β-OHB level and LVEF, c Linear regression and Pearson correlation analysis of β-OHB level and NTproBNP, d Mice with similar body weight were randomly assigned to the sham-treated group (n = 13) or MI group (n = 11), plasma β-OHB level was significantly increased, e Linear regression and Pearson correlation analysis of plasma β-OHB level and LVEF in mice of MI group, f Myocardial β-OHB was significantly increased in mouse 4 weeks after MI. ***P<0.001, ****P<0.0001

**Fig. 2** β-OHB enhanced cardiomyocyte death under hypoxic conditions. a, b Live (green) or dead (red) CMs under normoxia or 12 h of hypoxia in the different dose of β-OHB treated environment, c CCK-8 cell survival detection of CMs under normoxia or 12 h of hypoxia in the different dose of β-OHB treated environment, d LDH release in the culture media under normoxia or 12 h of hypoxia in the different dose of β-OHB treated environment **P<0.01, ****P<0.0001 vs. hypoxia 0 h. Scale bars, 50μm.

**Fig. 3** β-OHB altered glycolysis in cardiomyocytes under hypoxic conditions. a-f Representative western blot of enzymes involved in myocardial glycolysis in CMs cultured with β-OHB at 0 mM, 10 mM, 20 mM, or 50 mM under normoxia or hypoxia, g Immunofluorescence imaging showing GLUT1 expression in cardiomyocytes cultured with β-OHB under normoxia or hypoxia, h-k qPCR of enzymes involved in myocardial glycolysis in CMs cultured with β-OHB under normoxia or hypoxia, l Glucose in the culture media which cardiac myocytes cultured with β-OHB at different concentrations under normoxia or hypoxia. *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001.

**Fig. 4** β-OHB downregulated HIF-1α in cardiomyocytes in a dose-dependent manner under hypoxic conditions. **a-d** Western blot of HIF-1α in CMs cultured with β-OHB at different concentrations under normoxia or hypoxia, **e** PCR of HIF-1α in CMs cultured with β-OHB at different concentrations under normoxia or hypoxia, **f and h,** Western blot of GLUT1 and HIF-1α in HIF-1α siRNA transfection AC16 cells, **g and i** Western blot of GLUT1 and HIF-1α in HIF-1α overexpress (HIF-1α OE) AC16 cells.

**Fig. 5** Roxadustat partially reversed the effects of β-OHB in cardiomyocytes under hypoxic conditions. **a** Immunofluorescence imaging showing HIF-1α expression in cardiomyocytes cultured with 50 μM roxadustat and β-OHB under normoxia or hypoxia for 12 h, **b** Quantitation of HIF-1α in the nuclei of CMs cultured with 50 μM roxadustat and β-OHB under normoxia or hypoxia for 12 h, **c, d and e** Western blot of HIF-1α and GLUT1 expression in cardiomyocytes cultured with 50 μM roxadustat and β-OHB at different concentrations under normoxia or hypoxia, **f** Immunofluorescence imaging of GLUT1 in CMs cultured with 50 μM roxadustat and β-OHB under normoxia or hypoxia for 12 h, **g** Live (green) or dead (red) CMs cultured with 50 μM roxadustat and β-OHB at different concentrations under normoxia or hypoxia, **h** Quantitation of GLUT1 in CMs cultured with 50 μM roxadustat and β-OHB at different concentrations under normoxia or hypoxia for 12 h, **i** Quantitation of live cell percent in CMs cultured with 50 μM roxadustat and β-OHB at different concentrations under normoxia or hypoxia, **j, k** Western blot of VHL, PHD2 and HIF-1α expression in cardiomyocytes cultured with 50 μM roxadustat and β-OHB under normoxia or hypoxia for 12 h.* P<0.05, **P<0.01, ***P<0.001, ****P<0.0001

**Fig. 6** β-OHB metabolisms were obscured under hypoxic conditions in cardiac myocytes. **a** Diagrammatic drawing of ketone metabolism in the mitochondria. BDH1: β-OHB dehydrogenase; OXCT: succinyl-CoA:3-oxoacid-CoA transferase; ACAT1: acetyl-CoA acetyltransferase 1; TCA: tricarboxylic acid cycle, **b** Detected concentration of β-OHB in CMs cultured with β-OHB at different concentrations under normoxia or hypoxia, **c and d** Western blot of SLC16A1, BDH1, OXCT1, OXCT2 and ACTA1 which are β-OHB transporters and the key enzymes for ketone body metabolism in CMs cultured with β-OHB at different concentrations under normoxia or hypoxia, **e** ATP in CMs cultured with β-OHB at different concentrations under normoxia or hypoxia. * P<0.05, **P<0.01, ***P<0.001

**Fig. 7** KD exacerbated cardiac dysfunction in mice after MI surgery. **a** The level of β-OHB in plasma of model mice, **b** Triphenyl tetrazolium chloride staining and Masson’s trichrome staining 4weeks post-myocardial infarction, n=8 per group, **c** The infarct area was quantified to the left ventricular area, **d, e and f** left ventricular ejection fraction (LVEF) and fractional shorting (FS) were measured by echocardiography, n= 9–10 per group. **P<0.01**
Fig.8 Schematic diagram of how β-OHB exacerbates hypoxic/ischemic myocardial injury. Under hypoxia, β-OHB accumulation occurred in the cardiomyocytes and resulted in HIF-1α destabilization through regulated PHD/VHL. Then β-OHB induced more cardiomyocyte death by decreasing HIF-1α and the downstream GLUT1 and the expression of key glycolytic genes.
Figure 1

β-OHB levels were increased in response to MI in humans and mice. a Plasma 19 β-OHB levels in healthy volunteers (n = 32) or AMI patients (n = 45), b Linear 20 regression and Pearson correlation analysis of β-OHB level and LVEF, c Linear 21 regression and Pearson correlation analysis of β-OHB level and NTproBNP, d Mice 22 with similar body weight were randomly assigned to the sham-treated group (n = 13) or MI group (n = 11), plasma β-OHB level was significantly increased, e Linear 24 regression and Pearson correlation analysis of plasma β-OHB level and LVEF in mice 25 of MI group, f Myocardial β-OHB was significantly increased in mouse 4 weeks after 26 MI. ***P<0.001, ****P<0.0001
**Figure 2**

β-OHB enhanced cardiomyocyte death under hypoxic conditions. a, b Live 28 (green) or dead (red) CMs under normoxia or 12 h of hypoxia in the different dose of 29 β-OHB treated environment, c CCK-8 cell survival detection of CMs under normoxia 30 or 12 h of hypoxia in the different dose of β-OHB treated environment, d LDH release 31 in the culture media under normoxia or 12 h of hypoxia in the different dose of 32 β-OHB treated environment **P<0.01, ****P<0.0001 vs. hypoxia 0 h. Scale bars, 33 50μm.
Figure 3

β-OHB altered glycolysis in cardiomyocytes under hypoxic conditions. a-f Representative western blot of enzymes involved in myocardial glycolysis in CMs cultured with β-OHB at 0 mM, 10 mM, 20 mM, or 50 mM under normoxia or hypoxia, g Immunofluorescence imaging showing GLUT1 expression in cardiomyocytes cultured with β-OHB under normoxia or hypoxia, h-k qPCR of 39 enzymes involved in myocardial glycolysis in CMs cultured with β-OHB under normoxia or hypoxia, l Glucose in the culture
media which cardiac myocytes cultured with β-OHB at different concentrations under normoxia or hypoxia. *P<0.05,**P<0.01, ***P<0.001, ****P<0.0001.

Figure 4

β-OHB downregulated HIF-1α in cardiomyocytes in a dose-dependent manner under hypoxic conditions. a-d Western blot of HIF-1α in CMs cultured with β-OHB at 3 different concentrations under normoxia or hypoxia, e PCR of HIF-1α in CMs cultured with β-OHB at different concentrations under normoxia or hypoxia, f and h, 5 Western blot of GLUT1 and HIF-1α in HIF-1α siRNA transfection AC16 cells, g and i Western blot of GLUT1 and HIF-1α in HIF-1α overexpress (HIF-1α OE) AC16 7 cells.
Figure 5

Roxadustat partially reversed the effects of β-OHB in cardiomyocytes under 9 hypoxic conditions. a Immunofluorescence imaging showing HIF-1α expression in 10 cardiomyocytes cultured with 50 μM roxadustat and β-OHB under normoxia or 11 hypoxia for 12 h, b Quantitation of HIF-1α in the nuclei of CMs cultured with 50 μM 12 roxadustat and β-OHB under normoxia or hypoxia for 12 h, Western blot of HIF-1α in 13 CMs cultured with 50 μM roxadustat and β-OHB at different concentrations under 14 normoxia or hypoxia, c, d and e Western blot of HIF-1α and GLUT1 expression in 15 cardiomyocytes cultured with 50 μM roxadustat and β-OHB under normoxia or hypoxia for 12 h, f Immunofluorescence imaging of GLUT1 in CMs cultured with 50 17 μM roxadustat and β-OHB at different concentrations under normoxia or hypoxia, g 18 Live (green) or dead (red) CMs cultured with 50 μM roxadustat and β-OHB at 19 different concentrations under normoxia or hypoxia, h Quantitation of GLUT1 in 20 CMs cultured with 50 μM roxadustat and β-OHB at different concentrations under normoxia or hypoxia, i Quantitation of live cell percent in CMs cultured with 50 μM roxadustat and β-OHB 22 at different concentrations under normoxia or hypoxia, j, k Western blot of VHL, 23 PHD2 and HIF-1α expression in cardiomyocytes cultured with 50 μM roxadustat and 24 β-OHB under normoxia or hypoxia for 12 h.* P<0.05, **P<0.01, ***P<0.001, 25 ****P<0.0001
Figure 6

β-OHB metabolisms were obscured under hypoxic conditions in cardiac 27 myocytes. a Diagrammatic drawing of ketone metabolism in the mitochondria. BDH1: 28 β-OHB dehydrogenase; OXCT: succinyl-CoA:3-oxoacid-CoA transferase; ACAT1: 29 acetyl-CoA acetyltransferase 1; TCA: tricarboxylic acid cycle, b Detected 30 concentration of β-OHB in CMs cultured with β-OHB at different concentrations under normoxia or hypoxia, c and d Western blot of SLC16A1, BDH1, OXCT1, OXCT2 and ACTA1 which are β-
OHB transporters and the key enzymes for ketone 33 body metabolism in CMs cultured with β-OHB at different concentrations under 34 normoxia or hypoxia, e ATP in CMs cultured with β-OHB at different concentrations 35 under normoxia or hypoxia. * P<0.05, **P<0.01, ***P<0.001

Figure 7
KD exacerbated cardiac dysfunction in mice after MI surgery. a The level of 37 β-OHB in plasma of model mice, b Triphenyl tetrazolium chloride staining and 38 Masson’s trichrome staining 4weeks post-myocardial infarction, n=8 per group, c The 39 infarct area was quantified to the left ventricular area, d, e and f left ventricular 40 ejection fraction (LVEF) and fractional shorting (FS) were measured by 41 echocardiography, n= 9–10 per group. **P<0.01
Figure 8

Schematic diagram of how β-OHB exacerbates hypoxic/ischemic myocardial injury. Under hypoxia, β-OHB accumulation occurred in the cardiomyocytes and resulted in HIF-1α destabilization through regulated PHD/VHL. Then β-OHB induced more cardiomyocyte death by decreasing HIF-1α and the downstream GLUT1 and the expression of key glycolytic genes.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplement.pdf